MIZUHO MEDY CO.,LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,270 JPY | -0.15% |
|
-3.40% | +4.14% |
| 2021 | Mizuho Medy Co.,Ltd.(TSE:4595) added to S&P Global BMI Index | CI |
| 2020 | Mizuho Medy Co.,Ltd.(TSE:4595) dropped from S&P Global BMI Index | CI |
| Sales 2024 * | 9.5B 61.45M | Sales 2025 * | 10B 64.68M | Capitalization | 31.14B 201M |
|---|---|---|---|---|---|
| Net income 2024 * | 2.65B 17.14M | Net income 2025 * | 2.83B 18.3M | EV / Sales 2024 * | 2.07 x |
| Net cash position 2024 * | 11.47B 74.19M | Net cash position 2025 * | 12.44B 80.44M | EV / Sales 2025 * | 1.87 x |
| P/E ratio 2024 * |
11.8
x | P/E ratio 2025 * |
11
x | Employees | 180 |
| Yield 2024 * |
4.28% | Yield 2025 * |
4.59% | Free-Float | 53.62% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.15% | ||
| 1 week | -3.40% | ||
| Current month | -2.82% | ||
| 1 month | -0.15% | ||
| 3 months | -7.10% | ||
| 6 months | +12.84% | ||
| Current year | +4.14% |
1 week
3 270.00
3 380.00
1 month
3 195.003 445.00
Current year
3 105.003 820.00
1 year
2 010.003 890.00
3 years
1 774.004 275.00
5 years
1 024.004 275.00
10 years
360.004 275.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 79 | 77-11-01 | |
Tadashi Imamura
CTO | Chief Tech/Sci/R&D Officer | 65 | 84-03-31 |
Toshio Kambara
BRD | Director/Board Member | 60 | 94-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Katsumi Sasaki
BRD | Director/Board Member | 79 | 15-02-28 |
| Founder | 79 | 77-11-01 | |
Tadashi Imamura
CTO | Chief Tech/Sci/R&D Officer | 65 | 84-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 3,270 | -0.15% | 20,600 |
| 24-04-17 | 3,275 | -1.36% | 38,100 |
| 24-04-16 | 3,320 | -1.48% | 29,200 |
| 24-04-15 | 3,370 | -0.44% | 18,200 |
| 24-04-12 | 3,385 | 0.00% | 19,000 |
Delayed Quote Japan Exchange, April 18, 2024 at 02:00 am EDT
More quotes
MIZUHO MEDY CO., LTD. is a Japan-based company principally engaged in-vitro diagnostic pharmaceuticals business. The Company mainly provides in-vitro diagnostic pharmaceuticals, including immune serum test drugs, biochemical test drugs, urine and feces test drugs, microbial test drugs, blood test drugs, pathological test drugs and others, in hospital and medical practitioner fields. In addition, the Company also provides over-the-counter (OTC) drugs to pharmacies and drug stores, and sells fruit tree virus test drugs to which they apply the technology of immune serology test to agricultural test centers.
Calendar
2024-05-09
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.14% | 202M | |
| -1.59% | 12.58B | |
| -17.62% | 6.82B | |
| -3.93% | 5.14B | |
| -6.68% | 4.22B | |
| +0.53% | 4.21B | |
| -48.27% | 3.47B | |
| +7.09% | 2.65B | |
| -13.71% | 2.25B | |
| -3.40% | 1.69B |
- Stock Market
- Equities
- 4595 Stock
